Death toll rises to 36 following an explosion and fire at a southern India pharmaceutical factory
The fire department recovered the charred bodies of 34 workers from the accident site in an industrial area about 50 kilometers (31 miles) from the state capital Hyderabad, the state's fire services director G.V. Narayana Rao told The Associated Press.
Two other workers succumbed to burns and were pronounced dead in hospital, Rao said, adding that debris of the gutted pharmaceutical unit of Sigachi Industries was still being removed to find out if any more workers were trapped.
Nearly three dozen injured workers were admitted to hospitals, he said.
'The whole structure of the factory has collapsed. Fire has been doused, and we hope to finish removing the debris in the next few hours,' Rao said.
The explosion and subsequent fire was reported on Monday in the factory's spray dryer unit, which is used to process raw material into fine powder for making drugs, Rao said.
The state's Health Minister Damodar Raja Narasimha said there were 108 workers inside the factory at the time of the explosion.
'As bodies were badly burnt and mutilated, a special medical team has been deployed to conduct DNA tests', said Narasimha, adding the state government has set up a panel to investigate the cause of the incident.
Witnesses said they heard the explosion from a couple of kilometers away from the site.
India is home to some of the world's top pharmaceutical companies, playing a pivotal role in the global supply of generic medicines and vaccines. The country's robust manufacturing and cost-effective production have made it a hub for pharma giants.
Industrial accidents, particularly involving chemical reactors, aren't uncommon in such factories, underlining the need for authorities to implement stringent safety protocols and regulatory oversight in a sector critical to public health.
Sigachi Industries Limited is an Indian company dealing with active pharmaceutical ingredients, intermediates and vitamin-mineral blends, according to the company's website. It has five manufacturing facilities across India and subsidiaries in the U.S and the United Arab Emirates.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Mayors, doctor groups sue over Trump's efforts to restrict Obamacare enrollment
WASHINGTON (AP) — New Trump administration rules that give millions of people a shorter timeframe to sign up for the Affordable Care Act's health care coverage are facing a legal challenge from Democratic mayors around the country. The rules, rolled out last month, reverse a Biden-era effort to expand access to the Affordable Care Act's health insurance, commonly called 'Obamacare' or the ACA. The previous Democratic administration expanded the enrollment window for the coverage, which led to record enrollment. The Department of Health and Human Services rolled out a series of new restrictions for Obamacare late last month, just as Congress was weighing a major bill that will decrease enrollment in the health care program that Republican President Donald Trump has scorned for years. As many as 2 million people — nearly 10% — are expected to lose coverage from the health department's new rules. The mayors of Baltimore, Chicago and Columbus, Ohio sued the federal health department on Tuesday over the rules, saying they will result in more uninsured residents and overburden city services. 'Cloaked in the pretense of government efficiency and fraud prevention, the 2025 Rule creates numerous barriers to affordable insurance coverage, negating the purpose of the ACA to extend affordable health coverage to all Americans, and instead increasing the population of underinsured and uninsured Americans,' the filing alleges. Two liberal advocacy groups — Doctors for America and Main Street Alliance — joined in on the complaint. The federal health department announced a series of changes late last month to the ACA. It will shorten the enrollment period for the federal marketplace by a month, limiting it to Nov. 1 to Dec. 15 in 2026. Income verification checks will become more stringent and a $5 fee will be tacked on for some people who automatically re-enroll in a free plan. Insurers will also be able to deny coverage to people who have not paid their premiums on past plans. The rules also bar roughly 100,000 immigrants who were brought to the U.S. as children from signing up for the coverage. HHS said in a statement that the polices 'are temporary measures to immediately tamp down on improper enrollments and the improper flow of federal funds.' The mayors — all Democrats — argue that the polices were introduced without an adequate public comment period on the policies. 'This unlawful rule will force families off their health insurance and raise costs on millions of Americans. This does nothing to help people and instead harms Americans' health and safety across our country,' said Skye Perryman, the president of Democracy Forward, which is representing the coalition of plaintiffs in the lawsuit. The lawsuit does not challenge the Trump administration's restriction on immigrants signing up for the coverage. The Biden administration saw gains in Obamacare enrollment as a major success of the Democratic president's term, noting that a record 24 million people signed up for the coverage, thanks to generous tax breaks offered through the 2022 Inflation Reduction Act. But the program has been a target of Trump, who has said it is riddled with problems that make the coverage unaffordable for many without large subsidies. Enrollment in the program dipped during his first term in office.
Washington Post
5 hours ago
- Washington Post
Explosion at pharmaceutical factory in south India kills at least 36
At least 36 people were killed and dozens more injured in an explosion at a pharmaceutical factory in the southern Indian state of Telangana, state authorities said. The death toll is expected to rise as rescue workers continue to search the site following Monday's blast. Dozens of people remain missing. The blast occurred around 9 a.m. local time Monday at a plant in Pashamylaram, some 30 miles west of Hyderabad, the state capital. According to reports by local outlets, the explosion flattened a 4-story building and threw workers hundreds of feet. More than 140 people were on-site when the explosion occurred, officials told reporters. The bodies were 'badly burnt and mutilated,' Telangana Health Minister Damodar Raja Narasimha told the AP, and DNA tests were necessary to identify remains. The cause of the explosion is under investigation. Photos from the scene show rubble heaped stories high. The Telangana state government and Sigachi Industries, the operator of the factory, are set to pay 10 million rupees, around $117,000, to family members of each of the deceased, Telangana Chief Minister Revanth Reddy said in televised remarks. Injured workers are also set to receive compensation. Indian Prime Minister Narendra Modi expressed his condolences on X and pledged an additional 200,000 rupees, around $2,300, to the families of the deceased. The Pashamylaram plant is one of Sigachi's three manufacturing units, according to company documentation. India is the third-largest pharmaceutical industry in the world by volume and the leading supplier of generic medicines and vaccines. Labor and human rights watchdogs have warned of inadequate safety measures and lax oversight in some Indian factories. In a 2020 report on human rights in India, the U.S. State Department found that health and safety inspection capacity was insufficient and enforcement often poor. Global union federation InustriALL said that some 235 workers died across 116 industrial accidents in India between May 2020 and June 2021, according to media accounts and reports by the group's affiliates. The Pashamylaram blast came after a series of industrial accidents in the country. An August explosion at a chemical plant in Atchutapuram, in the neighboring state of Andhra Pradesh, left 17 workers dead. In May 2024, two unrelated explosions at chemical factories in Mumbai and the eastern state of Chhattisgarh killed at least 11, according to news items published by Britain's Royal Society of Chemistry. The 1984 Bhopal disaster, the world's worst industrial accident, occurred when a leak at a pesticide plant exposed hundreds of thousands of people in the central Indian city of Bhopal to a highly toxic gas and left a death toll in the thousands.
The Hill
7 hours ago
- The Hill
Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million
NEW YORK (AP) — Anne Wojcicki's bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. That means Wojcicki's nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe's assets for $305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. 'I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome,' Wojcicki said in a statement Monday — later adding that, 'the future of health care belongs to all of us.' The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for $256 million in May. But Wojcicki's nonprofit later topped that offer, winning the final round of bidding held last month. Under the deal, TTAM will acquire 23andMe's signature 'Personal Genome Service' provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavor proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a 'clear' difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be 'in the best position' as an independent bidder. Now that Wojcicki's nonprofit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah 'remain actively opposed to the sale.' In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale 'does not comply' with genetic privacy law in the state — and said it was 'disappointed' with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office and 23andMe for further comments on Tuesday. When announcing its intended sale to Wojcicki's nonprofit last month, 23andMe confirmed that TTAM 'has affirmed its commitment' to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, the company said, which includes allowing users to delete their data and 'opt out' of research. All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki added that, 'Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish.'
